19 related articles for article (PubMed ID: 38527694)
1. ABCB1 attenuates brain exposure to the KRAS
Rijmers J; Retmana IA; Bui V; Arguedas D; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
Biomed Pharmacother; 2024 Jun; 175():116720. PubMed ID: 38733773
[TBL] [Abstract][Full Text] [Related]
2. Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs.
Li W; Sparidans RW; Wang Y; Martins MLF; de Waart DR; van Tellingen O; Song JY; Lebre MC; van Hoppe S; Wagenaar E; Beijnen JH; Schinkel AH
Biomed Pharmacother; 2024 Jun; 175():116644. PubMed ID: 38692057
[TBL] [Abstract][Full Text] [Related]
3. P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.
Liao MZ; Gao C; Shireman LM; Phillips B; Risler LJ; Neradugomma NK; Choudhari P; Prasad B; Shen DD; Mao Q
Pharmacol Res; 2017 May; 119():61-71. PubMed ID: 28111265
[TBL] [Abstract][Full Text] [Related]
4. Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice.
Mairinger S; Zoufal V; Wanek T; Traxl A; Filip T; Sauberer M; Stanek J; Kuntner C; Pahnke J; Müller M; Langer O
Eur J Pharm Sci; 2018 Mar; 115():212-222. PubMed ID: 29360507
[TBL] [Abstract][Full Text] [Related]
5. Efflux transporters in drug disposition during pregnancy.
Chen X; Gao C; Han LW; Heidelberger S; Liao MZ; Neradugomma NK; Ni Z; Shuster DL; Wang H; Zhang Y; Zhou L
Drug Metab Dispos; 2024 May; ():. PubMed ID: 38811158
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
Li W; Tibben M; Wang Y; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2020 Mar; 146(6):1631-1642. PubMed ID: 31304590
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
[TBL] [Abstract][Full Text] [Related]
8. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
van Hoppe S; Rood JJM; Buil L; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
Mol Pharm; 2018 Nov; 15(11):5124-5134. PubMed ID: 30247919
[TBL] [Abstract][Full Text] [Related]
9. ABCB1 limits brain exposure of the KRAS
Loos NHC; Retmana IA; Li W; Martins MLF; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
Pharmacol Res; 2022 Apr; 178():106137. PubMed ID: 35192958
[TBL] [Abstract][Full Text] [Related]
10. The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib.
Martínez-Chávez A; Broeders J; Lebre MC; Tibben MT; Rosing H; Beijnen JH; Schinkel AH
Eur J Pharm Sci; 2021 Apr; 159():105740. PubMed ID: 33524505
[TBL] [Abstract][Full Text] [Related]
11. The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.
Loos NHC; Sparidans RW; Heydari P; Bui V; Lebre MC; Beijnen JH; Schinkel AH
Toxicol Appl Pharmacol; 2024 Apr; 485():116911. PubMed ID: 38527694
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
